This San Diego medtech company is cutting 117 jobs

CareFusion, a San Diego company that produces health care tools and technology, is laying off 117 workers to improve its operating efficiency.

The local business is a fully-owned subsidiary of New Jersey’s medical technology giant BD, or Becton Dickinson and Company. BD acquired CareFusion in 2014 for $12.2 billion.

The company is reducing its workforce at two local sites, including a number of engineering positions, according to the WARN notice BD filed with the state. There were 34 jobs cut at 3750 Torrey View Court and 83 job cuts at 10020 Pacific Mesa Boulevard.

The business segment affected by layoffs, BD Medical, is the top revenue driver for the company. One product of this BD unit are infusion pumps and syringes for IV drips in hospitals.

“As part of our efforts to ensure we are operating as efficiently and effectively as possible, BD is eliminating positions in our Medication Management Solutions business, though many of those positions are field service-based and a majority reside outside of the San Diego area,” a company spokesperson said in an email. “We are offering outplacement support, including job assistance resources, to help those impacted transition to new employment.”

The pharmaceutical giant said it remains committed to the region and employs nearly 4,000 people in the San Diego metropolitan area. Overall, BD has a global workforce of approximately 73,000 people, as of Sept. 30.

Element Biosciences raises $277 million

San Diego’s Element Biosciences is a rising star in the competitive realm of DNA sequencing and proved that once again by exceeding its recent fundraising goal. The local biotech brought in $277 million to help grow its global customer base and support its DNA sequencing technologies. Launched in 2017, Element makes benchtop DNA sequencing machines that allow scientists to probe the many facets of genetic data. Element – which counts San Diego’s Illumina, a leader of genome sequencing among its competitors – has raised more than $680 million to date.

Autobahn Therapeutics raises $100 million

Despite the tough fundraising environment for startups, another San Diego biotech managed to exceed its financing goal. Autobahn Therapeutics, which is developing novel treatments for people affected by depression and bipolar disorder, recently closed a $100 million financing round. In addition to well-know venture capital firms, Autobahn is backed by big pharma investors such as Biogen, Bristol Myers Squibb and Pfizer Ventures.

Local biotechnology company launches $167 million IPO

Another bright spot in what’s been a relatively slow, challenging year for the biotech IPO market, San Diego’s Artiva Biotherapeutics entered the Nasdaq on an upsized $167 million public offering. Artiva, which began trading on July 19 under the symbol “ARTV,” is developing cell therapies for people with autoimmune diseases and cancer. The primary goal of the financing will be to advance its natural killer cell therapy through clinical development for the treatment of lupus, solid tumors and blood cancers.

Originally Published: August 7, 2024 at 5:30 a.m.